ArticleExperimental biology and medicine (Maywood, N.J.)2021
Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
Article in Experimental biology and medicine (Maywood, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Mitigation of Oxidative Stress Pathways in the Diabetic Cornea and Lacrimal Glands Contributes to the Rapid Reversal of Diabetic Dry Eye by Naltrexone.Investigative ophthalmology & visual science · 2026Article
- Review
- Topical naltrexone increases aquaporin 5 production in the lacrimal gland and restores tear production in diabetic rats.Experimental biology and medicine (Maywood, N.J.) · 2024Article
- Elucidating the mechanism of corneal epithelial cell repair: unraveling the impact of growth factors.Frontiers in medicine · 2024Review
- Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats.Journal of diabetes and clinical research · 2023Article
- Opioids and Ocular Surface Pathology: A Literature Review of New Treatments Horizons.Journal of clinical medicine · 2022Review
- Sex Differences in Diabetic Ocular Surface Complications and Dysregulation of the OGF-OGFr Pathway.Journal of diabetes and clinical research · 2022Article
- Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin.Biochemical pharmacology · 2021Review
- Sex differences in the magnitude of diabetic ocular surface complications: Role of serum OGF.Physiology & behavior · 2021Article
- Systemic diseases and the cornea.Experimental eye research · 2021Review
- Dysregulation of the OGF-OGFr pathway and associated diabetic complications.Journal of diabetes and clinical research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The opioid growth factor (OGF)-OGF receptor (OGFr) pathway is present in the ocular surface and functions to maintain homeostasis of the epithelium. The OGF-OGFr pathway has been reported to be dysregulated in diabetic individuals and animal models, and is reflected in elevations of the inhibitory growth factor, OGF, chemically termed [Met
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.